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Animal models of rheumatoid pain:
experimental systems and insights
Bradford D. Fischer, Adeshina Adeyemo, Michael E. O’Leary and Andrea Bottaro*
Abstract
Severe chronic pain is one of the hallmarks and most debilitating manifestations of inflammatory arthritis. It
represents a significant problem in the clinical management of patients with common chronic inflammatory joint
conditions such as rheumatoid arthritis, psoriatic arthritis and spondyloarthropathies. The functional links between
peripheral inflammatory signals and the establishment of the neuroadaptive mechanisms acting in nociceptors and
in the central nervous system in the establishment of chronic and neuropathic pain are still poorly understood,
representing an area of intense study and translational priority. Several well-established inducible and spontaneous
animal models are available to study the onset, progression and chronicization of inflammatory joint disease, and
have been instrumental in elucidating its immunopathogenesis. However, quantitative assessment of pain in animal
models is technically and conceptually challenging, and it is only in recent years that inflammatory arthritis models
have begun to be utilized systematically in experimental pain studies using behavioral and neurophysiological
approaches to characterize acute and chronic pain stages. This article aims primarily to provide clinical and
experimental rheumatologists with an overview of current animal models of arthritis pain, and to summarize
emerging findings, challenges and unanswered questions in the field.
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Background
Arthritis pain in human patients
Rheumatoid arthritis (RA) and spondyloarthritis are
prevalent inflammatory-erosive joint diseases which
affect as many as 2% of the population worldwide, caus-
ing severe, debilitating morbidity and major economic
costs due to both health care expenditures and lost
productivity. Inflammatory arthritides are characterized
by progressive joint inflammation and destruction, de-
formity, loss of mobility, systemic manifestations and
severe pain which ultimately hamper basic motility
functions, activities of daily living and psychological
health in the affected individuals [1, 2].
Therapeutic approaches focused on the underlying in-
flammatory immunopathology have led to the introduction
of targeted biological disease-modifying anti-rheumatic
drugs (DMARDs), pioneered by anti-tumor necrosis factor
(TNF) agents, which have revolutionized the clinical
treatment and dramatically improved long-term out-
comes of these diseases [3, 4].
Pain, initially joint localized but often progressing to
widespread in advanced stages, is a major component of
inflammatory arthritis symptomatology and is typically
the primary reason for initial rheumatological referrals
[1, 2]. In a subset of patients with advanced disease,
chronic pain can also acquire typical neuropathic fea-
tures [1, 5]. These and other clinical findings support a
key role of neurosensitization mechanisms of nociceptive
pathways in the central nervous system in the establish-
ment of chronic arthritic pain.
The therapeutic success of biologic DMARDs has
provided new insights into the unique qualities of pain
manifestations associated with chronic inflammatory
arthritis. Notably, patients with a positive response to
anti-TNF agents often report rapid initial therapeutic
pain suppression which precedes the clinical anti-
inflammatory response [1, 6]. This is consistent with a
direct role of TNF and other inflammatory cytokines
like IL-6 and IL-17 on nociceptor sensitization pathways
[7]. Indeed, nociceptors in dorsal root ganglia have been
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shown to express TNF receptors and to directly respond
to TNF stimulation [7].
More problematic for the clinical management of
these diseases, however, is that a significant fraction of
patients fail to report long-term suppression of pain
comparable to their anti-inflammatory clinical response
to biologic and other DMARDs [1, 8–10]. Based on
these clinical observations and treatment outcomes,
therefore, direct inflammatory pain pathways are gener-
ally thought to predominate in early-stage arthritis,
evolving into chronic-neurogenic pain mechanisms over
time [1, 5].
From the patients’ perspective, effective management
of arthritis-associated pain is a primary therapeutic goal,
and a major component of patient-driven disease assess-
ment often underestimated by clinical disease activity
scoring tools [2, 10, 11]. A fuller mechanistic understand-
ing of the inflammatory and neuroadaptive mechanisms
leading to chronic arthritic pain is therefore required to
address a major unmet need in patient care.
This review will first describe existing animal models
of arthritis that are commonly utilized for preclinical
pain studies, discussing their specific advantages and
drawbacks. We will then provide key background on ex-
perimental methods for quantitative assessment of pain
responses in animal models, highlighting important
theoretical and practical challenges, and summarizing
recent insights into the mechanisms of arthritic pain.
Animal models of inflammatory joint disease
Animal disease models have proven invaluable to unravel
the pathophysiological pathways of inflammatory arthritis,
and for investigational testing of therapeutic agents. The
most commonly utilized animal species for this purpose
are mice and rats, either as strains that spontaneously de-
velop arthritis or as inducible models in which disease can
be provoked by administration of arthritogenic stimuli. A
number of comprehensive reviews have already covered
the range of animal arthritis models, and their features
in comparison to human disease pathophysiology and
therapeutic responses [12–15]. Here, we will briefly
summarize key aspects of a few relevant models, par-
ticularly with respect to features such as disease onset,
progression and chronicity which may affect their use
in pain studies.
Spontaneous arthritis models
Several rodent strains have been reported to be susceptible
to development of spontaneous arthritis, but experimental
studies have primarily focused on a few genetically
modified mouse strains which display full penetrance
and reproducible disease progression, especially K/BxN
and TNF-transgenic (TNFtg) mice [16, 17].
The K/BxN model K/BxN mice express a T-cell receptor
transgene specific for a peptide derived from the ubiqui-
tous enzyme glucose-6-phosphate isomerase (GPI), pre-
sented by the I-Ag7 MHC-II allele [17, 18]. Autoimmunity
manifests with onset of joint inflammation around 3–4
weeks of age, progressing over 4–8 weeks to full
inflammatory-erosive arthritis. Anti-GPI autoantibodies
appear to be the primary drivers of disease, because the
transfer of K/BxN serum, or even K/BxN-derived anti-GPI
monoclonal antibodies, is sufficient to induce arthritis in
other mouse strains (see later) [19]. Histologically, K/BxN
disease closely parallels findings in human RA joints,
including pannus formation, inflammatory infiltrates
and articular erosions. Therefore, K/BxN mice replicate
human RA both in the autoimmune pathophysiology
and key disease features.
The TNF-transgenic mouse model TNFtg mice, derived
in the early 1990s, express a human TNF gene lacking
post-transcriptional regulatory elements, and have pro-
vided cornerstone evidence for the involvement of TNF
in inflammatory arthritis [16]. Commonly used strains
range from a single copy (Tg(TNF)3647 strain) to mul-
tiple copies (Tg(TNF)197 strain and others) of the TNF
transgene [16, 20]. Other TNF-overexpressing strains
with similar disease features were later developed, but
will not be discussed here.
The 3647-strain TNFtg mice display delayed onset of
joint inflammation compared to multicopy transgenics
(6–8 weeks of age vs 3–4 weeks), slower disease progres-
sion (12–16 weeks from onset to maximal severity) and
increased lifespans (over a year with appropriate hus-
bandry) [16, 20]. Because of their late onset and slow
progression, single-copy TNFtg mice are particularly
suited for the study of processes associated with preclin-
ical disease stages and with progressing chronicity. Al-
though TNFtg disease is not autoimmunity driven, it
displays many of the histopathological findings of human
RA (synovial hyperplasia, neutrophilic inflammatory in-
filtrates and joint erosion) and other signs of systemic
inflammation. TNFtg mice are therefore an excellent
model to investigate TNF-induced inflammatory path-
ways in human disease.
Inducible arthritis models
Inflammatory arthritis can be induced experimentally in
many species, with well-established systems utilizing both
rats and mice. Arthritogenic signals in these models can
consist of nonspecific inflammatory agents, such as differ-
ent types of adjuvants; of immunization procedures using
specific antigens which cause self-tolerance breakdown; or
of passively administered autoreactive antibodies or sera.
Compared to spontaneous disease strains, advantages of
inducible models include their cost-effectiveness, reduced
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husbandry needs and reproducibility of existing protocols.
Disease typically develops rapidly, limiting the physio-
logical windows for the study of disease onset and pro-
gression. Penetrance, persistence and chronicity of
arthritis vary depending upon the model.
Adjuvant-induced arthritis and related models Arth-
ritis can be reproducibly induced in susceptible strains
of rats (e.g., Lewis or DA rats) by intradermal injection
of adjuvants, including complete or incomplete Freund’s
adjuvant (CFA, IFA), pristane and squalene, or intraarti-
cular administration of streptococcal cell wall products
or antigens in presensitized rats or mice [13, 21]. In
most applications, disease follows within days of admin-
istration, reaches maximal severity within one to a few
weeks and is typically followed by remission, which in
some protocols is reactivatable by repeated treatments.
Disease intensity and course vary depending on the strain
and arthritogenic signal. For instance, CFA-induced arth-
ritis is significantly more severe and systemic than that
induced by antigen-free adjuvants like IFA or pristane.
Pristane-induced arthritis in rats displays a remitting–re-
lapsing “flaring” pattern that resembles human RA. Al-
though the inciting stimulus in adjuvant-induced arthritis
is not antigenic, the resulting disease is often associated
with MHC-linked susceptibility, production of autoanti-
bodies and/or emergence of autoreactive T-cell clones,
reflecting an autoimmune pathophysiology [13].
Collagen-induced arthritis Collagen-induced arthritis
(CIA) is the most frequently utilized experimental model
of arthritis. Inflammatory arthritis is induced in genetic-
ally susceptible rats, mice, rabbits and other species by
immunization with type II collagen, typically of bovine
origin [22]. In a typical mouse protocol, polyarthritis
develops a few weeks post immunization with CFA-
emulsified collagen, reaching maximal clinical severity
within 2 weeks of onset and persisting in a chronic
state thereafter.
Antibody-induced arthritis Evidence that serum from
collagen-immunized rats and mice could passively in-
duce arthritis in recipients provided early experimental
confirmation of the direct pathogenic role of humoral
immunity in arthritis. The same approach is commonly
utilized to induce acute, transient arthritis in rats or
mice, in models such as collagen-antibody-induced arth-
ritis (CAIA) and K/BxN serum-transfer arthritis [19, 23].
Arthritis in these models is mediated by immune com-
plex deposition in the joints, recruitment of neutrophils
and other inflammatory innate components, and is inde-
pendent of B and T cells [19, 23]. Histologically, bone
and cartilage erosions and pannus formation closely re-
semble human RA. Because the inflammatory response
in the joints is rapid, reproducible and intense, the models
are best suited for the study of acute mechanisms.
CAIA can be induced in either rats or mice by intraven-
ous transfer of a mixture of anti-collagen II monoclonal
antibodies, most often accompanied by intraperitoneal
injection of LPS to potentiate the effect. Disease onset
follows rapidly after LPS injection, reaching maximal
severity in 4–5 days and waning in about an additional
week. Repeated injections can exacerbate and extend
the response.
Similarly, transfer of serum, antibodies or anti-GPI
monoclonals from K/BxN mice (see earlier) can induce
rapid (2–3 days) onset of polyarthritis in recipients, with
almost complete penetrance and without additional in-
ducers [19].
Experimental systems for analysis of pain-associated
responses in animal models
Self-reported pain scores are the primary means for
evaluating pain severity in patients. However, objective
assessment of pain in animals represents a significant
challenge for preclinical research, which has led to the
development of several experimental systems which
reproducibly mimic pathological pain conditions in
humans, including inflammatory and neuropathic pain,
and allow assessment of their outcomes. Broadly speaking,
animal behavioral models of pain consist of two principal
components: experimental manipulation intended to pro-
duce a pain-like state; and measurement of behavior pre-
sumably indicative of that pain state. These models can be
used to experimentally assess pain as well as its relief fol-
lowing the administration of antinociceptive drugs.
Current methods of pain assessment in animals were
initially developed in the context of models of induced
acute pain from different types of noxious stimuli, or of
neuropathic pain following experimental nerve injury,
but the same approaches are routinely applied to arth-
ritis pain models. All of these approaches have to over-
come the major conceptual hurdle of translating the
subjective experience of pain in animal subjects into
investigator-observable, quantifiable responses.
Broadly, experimental assessment of pain in animal
models relies on the quantification of pain-evoked or
pain-suppressed behaviors. Pain-evoked behaviors may
occur at very low rates in the absence of pain, and in-
crease in frequency following putative nociceptive stim-
uli. Examples include footpad withdrawal, jumping,
flinching or licking. In contrast, pain-suppressed behav-
iors are those that occur at high rates in the absence of
noxious stimuli and decrease in magnitude or duration
after exposure to a noxious stimulus. Some natural be-
haviors that may be suppressed in this context include
locomotor activity, nesting, motor coordination/balance
or feeding (e.g., [24]). In each case, measurable changes
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in behavior may result from pain responses to a normally
noxious stimulus, an enhanced response to low-grade
painful stimuli (hyperalgesia), or a painful response to a
normally non-noxious stimulus (allodynia).
Types of experimental pain models
The basic concept of measuring acute nociceptive pain
in animals relies on the input of a normally noxious
stimulus followed by the assessment of a withdrawal re-
sponse. The noxious stimulus can vary in intensity and
in modality, such as electrical, mechanical, thermal or
chemical [25, 26].
The advantage of these models largely rests in their
simplicity, their ability to objectively measure the with-
drawal response and their predictive value to assess
pharmacological effectiveness of opioid analgesics in
humans [25]. However, they have limited clinical rele-
vance and show impaired validity when nonopioid anal-
gesics are tested, such as steroids and nonsteroidal
anti-inflammatory drugs (NSAIDs). These and other
limitations have led to the development of additional
methods to behaviorally assess more clinically relevant
pain states, including models of acute and chronic in-
flammation and neuropathy.
Classic models of acute inflammatory pain include
the injection into the hind paw of rodents of chemicals
(e.g., formalin or carrageenan), which produce a rapid
nociceptive response characterized by paw flinching
and licking (formalin), and decreased response thresholds
to thermal and mechanical stimuli (i.e., allodynia and
hyperalgesia). Neuropathic pain in animals is classically
modeled by interventions that cause some degree of nerve
injury, such as ligation or chronic constriction. While
these systems have good predictive validity in pharmaco-
logical studies (e.g., sensitivity to opioids and anticonvul-
sants), they do not replicate the etiology of most human
neuropathic states, nor some of their common clinical
manifestations [27, 28].
These experimental systems have been instrumental to
unraveling basic neurophysiological pathways of noci-
ception and for pharmacological research, but because
of their limited clinical applicability they have been pro-
gressively complemented by more pathologically relevant
models of chronic and/or neuropathic pain, including
the inflammatory arthritis models already described.
Quantifying the perception of pain in animals
The assessment of pain in animals is naturally fraught
with conceptual and experimental complexities, and sig-
nificant research has been carried out in recent years to
standardize protocols, identify the impact of critical vari-
ables (such as sex, age, behavioral and environmental
factors), reduce investigator-associated subjectivity and
disruption, and expand the range of testable responses
from strictly sensory to include psychoaffective compo-
nents [26, 29–31]. A summary of commonly utilized
methods is presented in Table 1.
Pain-evoked behaviors The most frequently utilized
techniques for assessment of ongoing pain in experi-
mental animals rely on development of hyperalgesia and
allodynia, which can be quantitatively measured by
assessing withdrawal from non-noxious or subthreshold
stimuli. Arguably the most common mechanical stimuli
used for this purpose in rodents are von Frey hairs, elas-
tic filaments of varying diameter that buckle at a defined
force. Applied to the plantar surface of the paw when
the animal is positioned over a wire mesh surface, von
Frey hairs of increasing stiffness allow the determination
of the mechanical threshold of paw withdrawal. Although
less frequently utilized, electrical stimuli can also be ap-
plied briefly and quantifiably, and are reproduced
easily.
Lowered thresholds of evoked responses to stimuli
relative to controls are considered hallmarks of allodynia
and hyperalgesia. One limitation of these approaches lies
in the subjective measurement of withdrawal responses,
which can be obviated by use of automated electronic
systems [32, 33]. Assays based on evaluation of weight
bearing may be able to more objectively and physiologic-
ally identify postural changes in models of joint inflam-
mation [34].
Neurophysiologically, the primary caveat of mechan-
ical and electrical stimuli is that they activate both low-
threshold mechanoreceptors and nociceptors, preventing
a clear-cut distinction of the pathways involved. Thermal
stimulation is thought to be more specific in directly ac-
tivating nociceptive fibers. Commonly used methods in-
volve applying radiant heat or immersing the distal end
of the tail of a restrained animal into a thermostatic
water bath. Unrestrained animals can be tested using
Hargreaves’ method, during which radiant heat is ap-
plied to the plantar surface of the footpad via an infrared
source to elicit paw withdrawal.
Functional magnetic resonance imaging Functional
magnetic resonance imaging (fMRI) measures changes
in paramagnetic signals secondary to oxygen extraction
from oxyhemoglobin, reflecting metabolic activity in
brain tissue. Human fMRI studies have demonstrated ac-
tivation in specific brain structures following noxious
stimuli, including in the lateral thalamus, primary and
somatosensory cortex, insular cortex, anterior cingulate
cortex, striatum, cerebellum, supplemental motor area
and periaqueductal gray matter [35]. Small animal neu-
roimaging studies have validated the use of fMRI to
study pain in animals, showing activation in similar re-
gions [6, 36]. fMRI has the distinct advantage of being
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able to assess pain-related effects in brain areas thought
to be important in processing both sensory and affective
components. However, the approach requires trained
personnel and sophisticated equipment, and the use of
restraint or sedation to minimize head movement during
data acquisition adds obvious confounding variables.
Grimace scales Recent studies have analyzed facial ex-
pressions in animals in response to painful stimuli. A 10-
point facial expression (“grimace”) scale was developed in
mice based on orbital tightening (closed eyelid or eye
squeeze), nose bulge, cheek bulge, ear position and whisker
changes following intraperitoneal administration of acetic
acid [37]. Similar scales exist for rats and rabbits, and are
being evaluated for other species. Of note, analogous facial
expressions are exhibited by humans that verbally report
pain, and can be utilized to assess pain responses in nonver-
bal humans. Grimace scales have shown good reproducibil-
ity for trained investigators, especially in acute pain models,
and have the distinct advantage of allowing direct assess-
ment of pain in disease models in the absence of additional
experimental interventions. However, their applicability to
joint inflammation and chronic pain states remains to be
fully validated [38].
Pain-suppressed behaviors Although pain-evoked be-
haviors are most commonly utilized in animal pain stud-
ies, pain-suppressed behaviors have also been used to
assess pain in animals. These are defined by a decrease
of otherwise healthy behaviors that occur at high rates
(e.g., feeding, spontaneous ambulatory behavior) follow-
ing exposure to a noxious stimulus. These have clinical
correlates in human chronic pain patients, where sup-
pressed behaviors may include decreased activities of
daily living or ambulation, and correlate with signs of
clinical depression. Evidence of pain-suppressed behav-
iors in animals may be quantified by reduced feeding, re-
duced mating and/or reduced locomotor activity.
Decreased locomotor activity has been associated with
pain-like states in animals, including in rodent models of
inflammatory and neuropathic pain, although with some
discrepancies [39, 40]. As an example, Fig. 1 shows the
close quantitative correlation of decreased locomotor ac-
tivity in TNFtg mice with traditional clinical scores of
joint inflammation during disease progression. Models
of pain suppressed behaviors such as these can be used
to preclinically model the decreased activity observed in
patients with RA.
The inclusion of pain-suppressed behaviors in animal
testing has several advantages. First, pain-suppressed
Table 1 Experimental methods of pain assessment in rodent arthritis models
Assessment method
[example references]
Response measured Pain aspect assessed Advantages Disadvantages
Von Frey test/mechanical
hyperalgesia [6, 32, 33,
48–54, 56, 58, 59, 62]
Pain-evoked behavior:
withdrawal threshold from
a mechanical stimulus
Mechanical allodynia/
hyperalgesia
Quantitative, well-established
protocols
Stimulation of mechanical and
nociceptive fibers; possible
investigator bias/subjectivity
Hargreaves test/
thermonociception [6, 33,
51, 53, 54, 56–59, 62]
Pain-evoked behavior:
withdrawal latency from a
thermal stimulus
Thermal allodynia/
hyperalgesia
Quantitative, well-established
protocols; primary stimulation
of nociceptive fibers
Possible investigator bias/
subjectivity
Ambulatory/locomotor
behavior [53, 56, 59,
61–66]
Pain-suppressed behavior:
locomotion in an open field
Locomotor activity/
ambulation/exploratory
behavior
Automated quantitative
measurement; may include
affective component
May be affected by nonpain-
related outcomes (e.g., motor
function)
Grimace scales [38] Changes in facial
expressions associated
with pain
Expression of subjective
pain perception
Non-interventional; directly
linked to individual pain
state; may include affective
component
Possible investigator bias/
subjectivity; experimenter training
needed; further validation in
arthritis models required
fMRI [6] Functional changes in
CNS activity associated
with pain
Affective CNS responses
to pain
Objective measurements;
may include affective
component
Expensive equipment; high-level
investigator training needed;
requirement for restraint/
sedation
Gait/dynamic weight
bearing analysis [34, 59]
Changes in ambulatory
posture or weight
distribution
Spontaneous gait
changes due to joint
pain
Objective, quantitative
measurements; automated
systems available
Specialized equipment needed.
Operant conditioning
[60]
Behavior emitted to receive
a reward despite concurrent
exposure to a painful stimulus
Affective and/or
motivational
components of pain
perception
Objective, quantitative;
automated systems
available; may include
affective component
Specialized equipment needed
Escape/avoidance [45] Latency to escape noxious
stimulus
Affective and/or
motivational
components of pain
perception
Objective, quantitative;
automated systems
available; may include
affective component
Specialized equipment needed
CNS central nervous system, fMRI functional magnetic resonance imaging
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behaviors can be objectively measured using automated
equipment (e.g., locomotor activity box, operant response
chambers). Second, drugs that produce motor impairment
are less likely to produce false positive effects in pain-
suppressed assays relative to pain-stimulated behaviors.
Third, measures of pain-suppressed behaviors may be
used to investigate some of the psychoaffective compo-
nents of pain and may improve the translational validity of
these behaviors toward the clinic. At the same time, the
complexities of interpreting animal behavior from a psy-
choaffective standpoint cannot be understated, and im-
portant work needs to be carried out in this area to fully
validate these approaches [29, 30].
Operant conditioning and behavioral avoidance Simi-
lar to study of pain-suppressed behaviors, behavioral
methods can be utilized to explore affective and/or
motivational changes that occur in response to pain,
bypassing some of the problems associated with pain-
evoked responses. Operant procedures may require an
animal to predictably emit a defined behavioral response,
such as traversing a noxious stimulus (e.g., pass through
a heat source), in order to obtain in a positive reinforcer
(e.g., food treat) [41, 42]. Place avoidance or preference
paradigms are based on the assumption that animals will
display aversive behavior toward noxious stimuli (e.g.,
avoid heated cage areas) or preference for environments
associated with reward [43–45]. Changes in avoidance
behavior, such as in the presence of persistent pain states
or after experimental manipulations (e.g., analgesic drugs),
are thought to be related to changes in nociceptive path-
ways. Assays such as these can be used to study processes
that are thought to involve higher brain centers relative to
peripheral nociceptors.
Recent advances in animal models of arthritic pain
Although animal models of arthritis have been widely
utilized for decades to study not just disease pathogen-
esis and candidate therapeutics, only in the past 10–15
years have the biological properties of pain in these sys-
tems begun to be investigated systematically [46, 47].
Links between inflammation and pain-evoked responses
In all models studied, inflammatory disease is associated
with lowered thresholds to mechanical and thermal
stimulation, reflecting hyperalgesia and allodynia. How-
ever, thermal and mechanical hypersensitivity are not al-
ways closely correlated to each other, suggesting that
strain-specific and method-specific differences should be
considered in evaluating experimental outcomes [33]. In
addition, age may be an additional variable, because
adjuvant-induced arthritis evoked similar inflammatory
responses in young and old mice, but induced higher
levels of mechanical hypersensitivity in younger mice
using the von Frey test [48]. These discordances aside,
sensitization of pain pathways is typically concomitant
with the appearance of clinical signs of inflammation,
and in some cases it can precede them [46, 49]. This is
consistent with pain often being the earliest disease
manifestation in human RA patients [1, 50].
Studies focused on the resolution end of the disease
spectrum using transient antibody-induced arthritis (e.g.,
CAIA and K/BxN serum transfer) have shown that pain
sensitization can persist for extended periods of time be-
yond the resolution of inflammation [49, 51, 52]. This
also parallels the discordance between the therapeutic
control of inflammatory disease and persisting pain ex-
perienced by some human RA patients [2, 8–10]. Inter-
estingly, transfer into mice of anti-citrullinated peptide
antibodies from human RA patients was recently shown
to evoke pain-like induced and suppressed behaviors in
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Fig. 1 Correlation between locomotor activity and clinical disease
progression in TNFtg mice. a Ambulatory behavior, measured as
distance traveled in 60-minute experimental sessions (left, circles) was
assessed in female TNFtg mice (n = 5, filled symbols) and normal
littermates (n = 6, open symbols) every 2 weeks starting at 6 weeks
of age. At the same times, disease progression was assessed by
traditional clinical scoring of joint inflammation in each paw, on a
scale from 0 to 4/paw (maximum score = 16) (right, squares). Locomotor
activity was quantified in an open field arena (27.3 cm × 27.3 cm ×
20.3 cm) equipped with a computer interface and software (MED
Associates, St. Albans, VT, USA) and a 16-beam infrared array positioned
along the X and Y axes of the enclosure. Symbols represent means and
SEM for each data point. Note how the increases in clinical scores
in TNFtg mice (filled squares) parallel the decline in their locomotor
activity (filled circles) over time. b Example of recorded locomotor
tracings from a TNFtg mouse (left) and a WT littermate (right) at
16 weeks. Note the reduction in locomotor/exploratory behavior in
the TNFtg mouse. TNFtg TNF-transgenic
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the absence of a detectable inflammatory response, sug-
gesting that some pathogenic antibodies may mediate
nociceptive signals by distinct, non-inflammatory mech-
anisms [53].
Neurophysiology of inflammatory pain
Molecular and cellular studies of nociceptors and non-
neuronal cell types in dorsal root ganglia (DRG) and
spinal cord sensory pathways have begun to elucidate
the neurophysiological mechanisms of hyperalgesia in
models of arthritis and other inflammatory diseases
[32, 52, 54–56]. As in human patients, evidence is ac-
cumulating that arthritis chronicity in animal models is
associated not just with nociceptor sensitization, but
also with bona-fide neuropathic changes, as highlighted
by upregulated expression of the neuronal transcription
factor ATF3 and other stress markers in DRGs of long-
term arthritis models [33, 51, 52, 56, 57]. In the K/BxN
serum transfer model, the transition from acute to
chronic pain states was shown to be associated with
Toll-like receptor 4 function [58], making this molecule
and its potential endogenous ligands intriguing thera-
peutic targets.
Analgesia in chronic arthritis models
Pharmacologically, consistent with a neurogenic mech-
anism, persistent pain in both CAIA and K/BxN mice
appears to be alleviated by gabapentin, but not NSAIDs
[49, 51]. A role for leptin-dependent opioid reward
mechanisms and analgesia has been identified recently
in rat adjuvant-induced arthritis, potentially expanding
the usefulness of these models to human addiction stud-
ies [45]. TNF antagonists decreased pain responses, as
assessed by locomotor/behavioral test and mechanical
and thermal hyperalgesia, more rapidly than their anti-
inflammatory activity in a model of rat antigen-induced
monoarthritis and in TNFtg mice [6, 59]. The latter
results correlated with fMRI findings in both animals
and human patients, suggesting centrally mediated
pain modulation by TNF [6].
Pain-suppressed behavior in arthritis models
Various forms of pain-suppressed spontaneous behav-
iors, including locomotor activity, as well as operant re-
sponses and place avoidance have also been studied in
arthritis models, showing strong correlation with clinical
disease [45, 60–66]. While the kinetics of clinical disease
and suppression of locomotion appear to match closely
in rapid-onset models of arthritis [61, 63, 65], the more
slowly progressing K/BxN mouse strain displays a sig-
nificant delay between peak clinical progression and de-
creased mobility [64]. This finding is suggestive of a
psychoaffective component to the pain-suppressed be-
haviors in this strain. The possibility of depressive-like
behavior resulting from chronic inflammatory arthritis
was specifically investigated in TNFtg animals; however,
the study failed to identify neurobiological or behavioral
correlates of depression [66]. Whether these negative re-
sults reflect strain-dependent or experimental system
differences or can be generalized remains to be estab-
lished, but this is of course a crucial line of research due
to the known psychoaffective component of pain in hu-
man RA patients [1, 2].
Conclusions
Although no animal model perfectly recapitulates all
aspects of human inflammatory arthritis, the diversity
of existing models provides a large armamentarium for
elucidating specific pathophysiological mechanisms, in-
cluding the study of arthritic pain. In this respect, im-
portant criteria for model selection include relevant
pathophysiology and disease kinetics, especially with re-
gard to chronicity. Similarly, the array of systems currently
utilized for the experimental evaluation of pain perception
in animals—spanning from traditional quantitation of
hyperalgesia and allodynia-linked responses, to behavioral
studies, to the more recent neuroimaging and neurobio-
logical approaches—offers important experimental oppor-
tunities, while also requiring thoughtful consideration of
technical and interpretative caveats. Parallel progress in
these two fields will greatly broaden our understanding of
pain mechanisms beyond what can be achieved in human
studies.
Key priority targets for this research effort include
the mechanisms that establish pain chronicity and the
emergence of neuropathy in inflammatory arthritis, which
are critical for treatment and prevention of symptom pro-
gression. Despite the recent pharmacotherapeutic advances,
pain remains a major unresolved need in the management
of arthritis patients. Animal models have proven instru-
mental in providing key insights into the inflammatory
pathophysiology of arthritis, leading to the biological thera-
peutics revolution. Application of the same preclinical
approaches has great potential for the replication of this
success in treating rheumatoid pain.
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